Shopping Cart
- Remove All
- Your shopping cart is currently empty
ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $37 | In Stock | |
5 mg | $89 | In Stock | |
10 mg | $163 | In Stock | |
25 mg | $359 | In Stock | |
50 mg | $562 | In Stock | |
100 mg | $790 | In Stock | |
1 mL x 10 mM (in DMSO) | $98 | In Stock |
Description | ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF. |
In vitro | ML228 introduces a new chemical class for researchers exploring HIF activation and its therapeutic applications. Unlike existing HIF activators, ML228's structure significantly diverges, notably absent of the acidic functional group typically found in PHD inhibitors—an attribute potentially crucial for specific disease contexts[1][2]. |
In vivo | ML228 (injection; 1 µg/kg; 7 days) treatment following spinal cord injury (SCI) improves the local hypoxic-ischemic environment, reduces SCI secondary injury, and promotes neurological function recovery[3]. |
Molecular Weight | 415.49 |
Formula | C27H21N5 |
Cas No. | 1357171-62-0 |
Smiles | C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1 |
Relative Density. | 1.228 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 55 mg/mL (132.37 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.